Rudkin Brian B.
Brian B. Rudkin / DR2 - CNRS
Research interests
Research Director at the CNRS within the Stem Cell and Brain Research Institute (SBRI), Inserm U1208, University of Lyon and Co-Founder, in 2009, of the Joint Laboratory on Neuropathogenesis along with Prof. Chonggang YUAN at East China Normal University (ECNU) in Shanghai, integrated into the Key Laboratory of Brain Functional Genomics at the ECNU in January 2014.
The main objective is the transfer of fundamental discoveries using small antibody mimetics called peptide aptamers, to potential patient benefit in the context of the StemGamE platform.
The present transfer focus: • neurodegenerative diseases - e.g. ALS (Amyotrophic Lateral Sclerosis - Maladie de Charcot) • stimulation of the immune response e.g. for adoptive cell therapy of certain cancers • enhancement of safety of the use of embryonic stem cell-derived cultures for potential therapeutic benefit.
Member of Platforms
Selected Publications of Brian B. Rudkin
| Year |
Reference |
Title | Authors | Journal | PUB MED | ||
|---|---|---|---|---|---|---|---|
| 1999 | 10(7):1129-38 | Retroviral vectors for the expression of two genes in human multipotent neural precursors and their differentiated neuronal and glial progeny | Derrington EA, López-Lastra M, Chapel-Fernandez S, Cosset FL, Belin MF, Rudkin BB, Darlix JL | Hum Gene Ther | - | ||
| 1996 | 12(2):309-22 | Withdrawal of differentiation inhibitory activity/leukemia inhibitory factor up-regulates D-type cyclins and cyclin-dependent kinase inhibitors in mouse embryonic stem cells | Savatier P, Lapillonne H, van Grunsven LA, Rudkin BB, Samarut J | Oncogene | |||
| 1996 | 12(2):309-22 | Withdrawal of differentiation inhibitory activity/leukemia inhibitory factor up-regulates D-type cyclins and cyclin-dependent kinase inhibitors in mouse embryonic stem cells | Savatier P, Lapillonne H, van Grunsven LA, Rudkin BB, Samarut J | Oncogene | - | ||
| 1996 | 12(4):855-62 | Nerve growth factor-induced accumulation of PC12 cells expressing cyclin D1: evidence for a G1 phase block | van Grunsven LA, Thomas A, Urdiales JL, Machenaud S, Choler P, Durand I, Rudkin BB | Oncogene | - | ||
| 1996 | 12(6):1347-56 | Effect of nerve growth factor on the expression of cell cycle regulatory proteins in PC12 cells: dissection of the neurotrophic response from the anti-mitogenic response | van Grunsven LA, Billon N, Savatier P, Thomas A, Urdiales JL, Rudkin BB | Oncogene | - | ||
| 1996 | 12(6):1347-56 | Effect of nerve growth factor on the expression of cell cycle regulatory proteins in PC12 cells: dissection of the neurotrophic response from the anti-mitogenic response | van Grunsven LA, Billon N, Savatier P, Thomas A, Urdiales JL, Rudkin BB | Oncogene | |||
| 2013 | 12(7):1939-52 | Calcineurin A versus NS5A-TP2/HD domain containing 2: a case study of site-directed low-frequency random mutagenesis for dissecting target specificity of peptide aptamers | Dibenedetto S, Cluet D, Stebe PN, Baumle V, Léault J, Terreux R, Bickle M, Chassey BD, Mikaelian I, Colas P, Spichty M, Zoli M, Rudkin BB | Mol Cell Proteomics | - | ||
| 1996 | 13(10):2047-54 | The CDK inhibitor p21WAF1/Cip1 is induced through a p300-dependent mechanism during NGF-mediated neuronal differentiation of PC12 cells | Billon N, van Grunsven LA, Rudkin BB | Oncogene | - | ||
| 1997 | 14(3):265-75 | Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations | Rossel M, Pasini A, Chappuis S, Geneste O, Fournier L, Schuffenecker I, Takahashi M, van Grunsven LA, Urdiales JL, Rudkin BB, Lenoir GM, Billaud M | Oncogene | - | ||
| 2014 | 15 Suppl 14:S5 | EXACT2: the semantics of biomedical protocols | Soldatova LN, Nadis D, King RD, Basu PS, Haddi E, Baumlé V, Saunders NJ, Marwan W, Rudkin BB | BMC Bioinformatics | - | ||